Jennifer Johnson
About Jennifer Johnson
Jennifer Johnson is a Postdoctoral Researcher at Capricor Therapeutics, where she focuses on exosomes platform technology for cardiac diseases. She holds a Doctorate in Biochemistry and Philosophy from Georgia Institute of Technology and has contributed to the development of therapies for heart failure and related conditions.
Work at Capricor Therapeutics
Jennifer Johnson has been employed as a Postdoctoral Researcher at Capricor Therapeutics, Inc. since 2015. Her work focuses on the research and development of innovative therapies for cardiac diseases. She participates in projects involving exosomes platform technology, which aims to enhance treatment options for heart conditions. Johnson has also contributed to the development of Cenderitide, a natriuretic peptide receptor agonist designed for outpatient heart failure treatment. Additionally, she has played a role in the advancement of CAP-1002, a cardiac cell therapy targeting post-myocardial infarction, advanced heart failure, and Duchenne muscular dystrophy associated cardiomyopathy.
Education and Expertise
Jennifer Johnson holds a Doctor of Philosophy degree in Biochemistry and Philosophy from the Georgia Institute of Technology, where she studied from 2010 to 2015. Prior to her doctoral studies, she earned a Bachelor of Science degree in Chemistry from Valdosta State University, completing her undergraduate education from 2006 to 2009. Her academic background provides a strong foundation in biochemical research and therapeutic development, particularly in the context of cardiac health.
Background
Before joining Capricor Therapeutics, Jennifer Johnson worked as a Graduate Research Assistant at the Georgia Institute of Technology from 2010 to 2015. During this five-year period, she gained valuable research experience in a rigorous academic environment. Additionally, she served as a Laboratory Technician at Arysta Lifescience for six months in 2010, where she further developed her practical laboratory skills in Dublin, Ireland.
Research Contributions
Jennifer Johnson has made significant contributions to the field of cardiac research through her involvement in the development of therapies aimed at treating heart diseases. Her work on Cenderitide and CAP-1002 highlights her commitment to advancing treatment options for patients with heart failure and related conditions. These projects reflect her expertise in biochemistry and her dedication to improving cardiac health outcomes.